PHI-101

• Description:

  PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  386.44

• Molecular Formula:

  C19H19FN4O2S

• Notes:

  Research use only, not for human use.

• Receptor:

  Chk

• CAS Number:

  2127107-15-5